Upcoming Deadline for Tenax Therapeutics Class Action - Investors urged to act

Tenax Therapeutics Class Action Lawsuit: Important Updates for Investors

Investors of Tenax Therapeutics, Inc. (NASDAQ: TENX) are facing a crucial deadline related to an anticipated class-action lawsuit concerning alleged securities misrepresentation. This information comes from Levi & Korsinsky, LLP, reminding those who purchased shares from November 13, 2023, to August 7, 2026, to consider their eligibility for compensation, given significant losses in the company's stock value.

Overview of the Situation

On August 10, 2026, Tenax Therapeutics reported results from the Phase 3 LEVEL trial for its lead asset, TNX-103 (oral levosimendan). The announcement indicated that the trial failed to meet both its primary endpoint, the 6-minute walk distance (6MWD), and a key secondary endpoint related to patient symptoms. This news led to an astonishing drop in share price, with Tenax shares losing nearly 90% of their value, resulting in a staggering 89.77% decrease since reporting.

The lawsuit's foundation lies in the claims that investors were misled about the drug's efficacy and the expectations surrounding the trial outcomes. Tenax's prior communications suggested that TNX-103 would yield favorable results based on earlier Phase 2 trial data, which had shown promise. However, the failure of the larger Phase 3 trial has cast doubts on these representations and raised serious concerns regarding the company's integrity and transparency.

Legal Context and Timeline

Investors interested in participating in the legal action need to act quickly. The deadline for seeking lead plaintiff status in this securities class action is December 28, 2026. Those who bought shares at allegedly inflated prices during the class period could potentially qualify for recovery. Levi & Korsinsky is prepared to assist with this process at no upfront cost.

To participate, investors should gather their brokerage statements and any trade confirmations that detail their purchase dates, quantity of shares, and corresponding prices. This information will be essential to evaluate potential eligibility for recovery.

Details of the Allegations

The heart of the matter lies in the alleged misstatements made by Tenax regarding the efficacy of TNX-103 prior to the release of the trial results. The complaint details how the company allegedly communicated misleading information suggesting that the drug had a higher likelihood of success than was actually the case. Furthermore, it is contended that Tenax's claims about the drug's